Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Facioscapulohumeral muscular dystrophy market is set to expand through 2034 with gene therapy innovation and FDA acceleration Facioscapulohumeral muscular dystrophy market to expand across 7MM by 2034, driven by gene therapy, rising diagnosis, and key drug launches from Roche, Avidity, and Epicrispr. bySoujanya RaviJuly 18, 2025